Howard L Weiner

List of Publications by Year
in descending order

209 papers	23,641 citations	13099 68 h-index	8630 146 g-index
230 all docs	230 docs citations	230 times ranked	26614 citing authors

#	Article	IF	Citations
1	Identification of a unique TGF-Î²â€“dependent molecular and functional signature in microglia. Nature Neuroscience, 2014, 17, 131-143.	14.8	2,056
2	The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity, 2017, 47, 566-581.e9.	14.3	1,741
3	Alterations of the human gut microbiome in multiple sclerosis. Nature Communications, 2016, 7, 12015.	12.8	957
4	T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosis. Nature, 1990, 346, 183-187.	27.8	866
5	Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature, 1995, 376, 177-180.	27.8	765
6	Induction and mechanism of action of transforming growth factorâ€Î²â€secreting Th3 regulatory cells. Immunological Reviews, 2001, 182, 207-214.	6.0	760
7	Differential roles of microglia and monocytes in the inflamed central nervous system. Journal of Experimental Medicine, 2014, 211, 1533-1549.	8.5	711
8	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 2019, 365, .	12.6	710
9	Oral tolerance. Immunological Reviews, 2005, 206, 232-259.	6.0	630
10	Multiple Sclerosis: Mechanisms and Immunotherapy. Neuron, 2018, 97, 742-768.	8.1	610
11	Microglial signatures and their role in health and disease. Nature Reviews Neuroscience, 2018, 19, 622-635.	10.2	599
12	The Host Shapes the Gut Microbiota via Fecal MicroRNA. Cell Host and Microbe, 2016, 19, 32-43.	11.0	570
13	Oral tolerance. Immunological Reviews, 2011, 241, 241-259.	6.0	488
14	Loss of â€˜homeostaticâ€™ microglia and patterns of their activation in active multiple sclerosis. Brain, 2017, 140, 1900-1913.	7.6	475
15	Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nature Medicine, 2014, 20, 1147-1156.	30.7	380
16	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet, The, 2016, 387, 1075-1084.	13.7	379
17	Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Annals of Neurology, 1986, 19, 578-587.	5.3	355
18	Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort. JAMA Neurology, 2015, 72, 152.	9.0	328

#	Article	IF	Citations
19	Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nature Neuroscience, 2019, 22, 729-740.	14.8	327
20	The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?. Annals of Neurology, 2009, 65, 239-248.	5.3	312
21	Nasal administration of amyloid-? peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Annals of Neurology, 2000, 48, 567-579.	5.3	311
22	Immunology and immunotherapy of Alzheimer's disease. Nature Reviews Immunology, 2006, 6, 404-416.	22.7	301
23	Multiple Sclerosis Is an Inflammatory T-Cellâ€“Mediated Autoimmune Disease. Archives of Neurology, 2004, 61, 1613.	4.5	238
24	Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25â^'LAP+ T cells. Nature Medicine, 2006, 12, 627-635.	30.7	229
25	CD4+CD25â^' T Cells That Express Latency-Associated Peptide on the Surface Suppress CD4+CD45RBhigh-Induced Colitis by a TGF-Î²-Dependent Mechanism. Journal of Immunology, 2003, 170, 2516-2522.	0.8	221
26	IL-4 is a differentiation factor for transforming growth factor-Î² secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. European Journal of Immunology, 1998, 28, 2780-2790.	2.9	210
27	A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. Journal of Neurology, 2008, 255, 3-11.	3.6	191
28	The mucosal milieu creates tolerogenic dendritic cells and TR1 and TH3 regulatory cells. Nature Immunology, 2001, 2, 671-672.	14.5	185
29	Smoking and Disease Progression in Multiple Sclerosis. Archives of Neurology, 2009, 66, 858-64.	4.5	182
30	Mesenteric lymph nodes are critical for the induction of high-dose oral tolerance in the absence of Peyer's patches. European Journal of Immunology, 2002, 32, 1109-1113.	2.9	167
31	A probiotic modulates the microbiome and immunity in multiple sclerosis. Annals of Neurology, 2018, 83, 1147-1161.	5.3	158
32	AHR Activation Is Protective against Colitis Driven by T Cells in Humanized Mice. Cell Reports, 2016, 17, 1318-1329.	6.4	147
33	Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy, 2016, 8, 889-906.	2.0	147
34	Immunologic Mechanisms and Therapy in Multiple Sclerosis. Immunological Reviews, 1995, 144, 75-107.	6.0	142
35	Blood neurofilament light: a critical review of its application to neurologic disease. Annals of Clinical and Translational Neurology, 2020, 7, 2508-2523.	3.7	132
36	A model for the comprehensive investigation of a chronic autoimmune disease: The multiple sclerosis CLIMB study. Autoimmunity Reviews, 2006, 5, 532-536.	5.8	130

#	Article	IF	Citations
37	Latency-Associated Peptide Identifies a Novel CD4+CD25+ Regulatory T Cell Subset with TGFÎ²-Mediated Function and Enhanced Suppression of Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2008, 180, 7327-7337.	0.8	129
38	QTL influencing autoimmune diabetes and encephalomyelitis map to a 0.15-cM region containing Il2. Nature Genetics, 1999, 21, 158-160.	21.4	127
39	Microbiota Signaling Pathways that Influence Neurologic Disease. Neurotherapeutics, 2018, 15, 135-145.	4.4	127
40	Exploration of machine learning techniques in predicting multiple sclerosis disease course. PLoS ONE, 2017, 12, e0174866.	2.5	122
41	Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy. Journal of Magnetic Resonance Imaging, 2002, 15, 203-209.	3.4	118
42	Oral Administration of miR-30d from Feces of MS Patients Suppresses MS-like Symptoms in Mice by Expanding Akkermansia muciniphila. Cell Host and Microbe, 2019, 26, 779-794.e8.	11.0	118
43	Oral tolerance induced by continuous feeding: enhanced up-regulation of transforming growth factor-Î²/interleukin-10 and suppression of experimental autoimmune encephalomyelitis. Journal of Autoimmunity, 2003, 20, 135-145.	6.5	115
44	Neurofilament light chain serum levels correlate with 10â€year <scp>MRI</scp> outcomes in multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1478-1491.	3.7	115
45	Gut Microbiome in Progressive Multiple Sclerosis. Annals of Neurology, 2021, 89, 1195-1211.	5.3	115
46	Investigation of probiotics in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 58-63.	3.0	112
47	Orally administered myelin basic protein in neonates primes for immune responses and enhances experimental autoimmune encephalomyelitis in adult animals. European Journal of Immunology, 1994, 24, 1026-1032.	2.9	110
48	Microglia inhibit photoreceptor cell death and regulate immune cell infiltration in response to retinal detachment. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6264-E6273.	7.1	104
49	Neuroimmunology I: Immunoregulation in neurological disease. Annals of Neurology, 1982, 11, 437-449.	5.3	97
50	Transcriptional signature of human pro-inflammatory TH17 cells identifies reduced IL10 gene expression in multiple sclerosis. Nature Communications, 2017, 8, 1600.	12.8	93
51	Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin-4 production and associated eosinophilia. Annals of Neurology, 1997, 42, 313-318.	5.3	92
52	B Cell-Deficient (Î¼MT) Mice Have Alterations in the Cytokine Microenvironment of the Gut-Associated Lymphoid Tissue (GALT) and a Defect in the Low Dose Mechanism of Oral Tolerance. Journal of Immunology, 2001, 166, 4456-4464.	0.8	92
53	Immunoregulatory T-cells and lymphocytotoxic antibodies in active multiple sclerosis: Weekly analysis over a six-month period. Annals of Neurology, 1983, 13, 418-425.	5.3	90
54	In vivo labeling of blood T cells: Rapid traffic into cerebrospinal fluid in multiple sclerosis. Annals of Neurology, 1987, 22, 89-93.	5.3	90

#	Article	IF	Citations
55	IL-10-dependent Tr1 cells attenuate astrocyte activation and ameliorate chronic central nervous system inflammation. Brain, 2016, 139, 1939-1957.	7.6	87
56	Calorie restriction slows age-related microbiota changes in an Alzheimerâ€™s disease model in female mice. Scientific Reports, 2019, 9, 17904.	3.3	86
57	Dominant role of microglial and macrophage innate immune responses in human ischemic infarcts. Brain Pathology, 2018, 28, 791-805.	4.1	85
58	Age dependent susceptibility to reovirus type 3 encephalitis: Role of viral and host factors. Annals of Neurology, 1983, 13, 602-607.	5.3	82
59	Loss of functional suppression is linked to decreases in circulating suppressor inducer (CD4 + 2H4 +) T Cells in multiple sclerosis. Annals of Neurology, 1988, 24, 185-191.	5.3	79
60	Cutting Edge: Immature Human Dendritic Cells Express Latency-Associated Peptide and Inhibit T Cell Activation in a TGF-Î²-Dependent Manner. Journal of Immunology, 2007, 178, 4017-4021.	0.8	79
61	Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle and Nerve, 2018, 58, 261-269.	2.2	78
62	Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e267.	6.0	77
63	An immunoregulatory and tissue-residency program modulated by c-MAF in human TH17 cells. Nature Immunology, 2018, 19, 1126-1136.	14.5	77
64	Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin antigens: IV. Suppression of chronic relapsing disease in the lewis rat and strain 13 guinea pig. Annals of Neurology, 1991, 29, 615-622.	5.3	74
65	Novel CD8⁺ Treg suppress EAE by TGFâ€Î²â€•and IFNâ€Î³â€dependent mechanisms. European Journal of Immunology, 2009, 39, 3423-3435.	2.9	74
66	Reciprocal expression of co-stimulatory molecules, B7-1 and B7-2, on murine T cells following activation. European Journal of Immunology, 1995, 25, 207-211.	2.9	73
67	Induction of Colitis in Mice Deficient of Peyer's Patches and Mesenteric Lymph Nodes Is Associated with Increased Disease Severity and Formation of Colonic Lymphoid Patches. American Journal of Pathology, 2002, 161, 2273-2282.	3.8	73
68	Extracellular RNAs: development as biomarkers of human disease. Journal of Extracellular Vesicles, 2015, 4, 27495.	12.2	72
69	Platelets Play Differential Role During the Initiation and Progression of Autoimmune Neuroinflammation. Circulation Research, 2015, 117, 779-792.	4.5	72
70	Systematic evaluation of RNA quality, microarray data reliability and pathway analysis in fresh, fresh frozen and formalin-fixed paraffin-embedded tissue samples. Scientific Reports, 2018, 8, 6351.	3.3	71
71	Oral Administration of OKT3 Monoclonal Antibody to Human Subjects Induces a Dose-Dependent Immunologic Effect in T Cells and Dendritic Cells. Journal of Clinical Immunology, 2010, 30, 167-177.	3.8	69
72	Common Tâ€cell receptor V Î² usage in oligoclonal T lymphocytes derived from cerebrospinal fluid and blood of patients with multiple sclerosis. Annals of Neurology, 1991, 29, 33-40.	5.3	68

#	Article	IF	Citations
73	Suppression of antigen-induced arthritis in lewis rats by oral administration of type ii collagen. Arthritis and Rheumatism, 1995, 38, 1092-1096.	6.7	65
74	TGF-Î² Induces Surface LAP Expression on Murine CD4 T Cells Independent of Foxp3 Induction. PLoS ONE, 2010, 5, e15523.	2.5	64
75	Decrease of suppressor inducer (cd4+ 2h4+) t cells in multiple sclerosis cerebrospinal fluid. Annals of Neurology, 1989, 25, 494-499.	5.3	63
76	Genetic susceptibility or resistance to autoimmune encephalomyelitis in MHC congenic mice is associated with differential production of pro- and anti-inflammatory cytokines. International Immunology, 1999, 11, 1573-1580.	4.0	63
77	Childhood multiple sclerosis: Clinical features and demonstration of changes in T cell subsets with disease activity. Annals of Neurology, 1982, 11, 463-468.	5.3	60
78	Identification of MS-specific serum miRNAs in an international multicenter study. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e491.	6.0	59
79	Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. Neurology, 2014, 83, 2219-2226.	1.1	58
80	Targeting latency-associated peptide promotes antitumor immunity. Science Immunology, 2017, 2, .	11.9	58
81	Evaluating more naturalistic outcome measures. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e162.	6.0	57
82	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Multiple Sclerosis Journal, 2019, 25, 1605-1617.	3.0	57
83	COVID-19 in teriflunomide-treated patients with multiple sclerosis. Journal of Neurology, 2020, 267, 2790-2796.	3.6	56
84	History and mechanisms of oral tolerance. Seminars in Immunology, 2017, 30, 3-11.	5.6	55
85	Acute microglia ablation induces neurodegeneration in the somatosensory system. Nature Communications, 2018, 9, 4578.	12.8	55
86	Infection of neuronal cell cultures with reovirus mimics in vitro patterns of neurotropism. Annals of Neurology, 1984, 16, 603-610.	5.3	54
87	Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis. Neurology, 2014, 82, 2173-2179.	1.1	54
88	Predicting Clinical Progression in Multiple Sclerosis With the Magnetic Resonance Disease Severity Scale. Archives of Neurology, 2008, 65, 1449.	4.5	53
89	Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity. JAMA Neurology, 2017, 74, 275.	9.0	52
90	Different kinetic patterns of cytokine gene expressionin vivo in orally tolerant mice. European Journal of Immunology, 1994, 24, 2720-2724.	2.9	51

#	Article	IF	Citations
91	Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium. Journal of Extracellular Vesicles, 2015, 4, 26533.	12.2	51
92	Î³Î´ T cells control humoral immune response by inducing T follicular helper cell differentiation. Nature Communications, 2018, 9, 3151.	12.8	51
93	Current Issues in the Treatment of Human Diseases by Mucosal Tolerance. Annals of the New York Academy of Sciences, 2004, 1029, 211-224.	3.8	50
94	Seasonal variation of interferonâ€Î³ production in progressive multiple sclerosis. Annals of Neurology, 1998, 44, 824-828.	5.3	49
95	7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions. Multiple Sclerosis Journal, 2020, 26, 177-187.	3.0	49
96	Effect of vitamin D on MS activity by disease-modifying therapy class. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e167.	6.0	47
97	Control of the gut microbiome by fecal microRNA. Microbial Cell, 2016, 3, 176-177.	3.2	47
98	An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	47
99	Identification and characterization of latency-associated peptide-expressing Î³Î´ T cells. Nature Communications, 2015, 6, 8726.	12.8	45
100	Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk. Annals of Neurology, 2016, 79, 178-189.	5.3	45
101	Improved relapse recovery in paediatric compared to adult multiple sclerosis. Brain, 2020, 143, 2733-2741.	7.6	45
102	A pharmacogenetic study implicates <scp>SLC9a9</scp> in multiple sclerosis disease activity. Annals of Neurology, 2015, 78, 115-127.	5.3	39
103	Dynamic regulation of serum aryl hydrocarbon receptor agonists in MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e359.	6.0	37
104	Power estimation for non-standardized multisite studies. NeuroImage, 2016, 134, 281-294.	4.2	36
105	Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e200.	6.0	35
106	Dualâ€Sensitivity Multiple Sclerosis Lesion and CSF Segmentation for Multichannel 3T Brain MRI. Journal of Neuroimaging, 2018, 28, 36-47.	2.0	35
107	Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. Npj Digital Medicine, 2019, 2, 123.	10.9	35
108	Temporal association of sNfL and gadâ€enhancing lesions in multiple sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 945-955.	3.7	35

#	Article	IF	Citations
109	Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. Journal of Neuroimaging, 2017, 27, 481-485.	2.0	34
110	MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis. Journal of the Neurological Sciences, 2014, 346, 250-254.	0.6	31
111	Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation. Journal of Neuroinflammation, 2015, 12, 245.	7.2	31
112	Social support in multiple sclerosis: Associations with quality of life, depression, and anxiety. Journal of Psychosomatic Research, 2020, 138, 110252.	2.6	31
113	Type 1 human poliovirus binds to human synaptosomes. Annals of Neurology, 1987, 21, 64-70.	5.3	30
114	Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. Multiple Sclerosis and Related Disorders, 2019, 35, 119-127.	2.0	30
115	Gray matter microglial activation in relapsing vs progressive MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e587.	6.0	30
116	An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. Multiple Sclerosis Journal, 2014, 20, 1381-1390.	3.0	29
117	The sex-specific interaction of the microbiome in neurodegenerative diseases. Brain Research, 2019, 1724, 146385.	2.2	29
118	Immunosuppressive treatment in multiple sclerosis. Journal of the Neurological Sciences, 2004, 223, 1-11.	0.6	28
119	MRI phenotypes in MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e530.	6.0	28
120	Treatment Satisfaction in Multiple Sclerosis. International Journal of MS Care, 2014, 16, 68-75.	1.0	28
121	Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study. Npj Digital Medicine, 2020, 3, 135.	10.9	27
122	Three-year Open Protocol Continuation Study of Oral Tolerization with Myelin Antigens in Multiple Sclerosis and Design of a Phase III Pivotal Trial. Annals of the New York Academy of Sciences, 1996, 778, 243-250.	3.8	26
123	Pathogenic Transdifferentiation of Th17 Cells Contribute to Perpetuation of Rheumatoid Arthritis during Anti-TNF Treatment. Molecular Medicine, 2015, 21, 536-543.	4.4	26
124	Disruption of the <scp>ATP</scp>/adenosine balance in <scp>CD</scp>39^{â˜'/â˜'} mice is associated with handlingâ€induced seizures. Immunology, 2017, 152, 589-601.	4.4	25
125	Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression. Multiple Sclerosis Journal, 2020, 26, 1708-1718.	3.0	25
126	Aberrant expression of USF2 in refractory rheumatoid arthritis and its regulation of proinflammatory cytokines in Th17 cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30639-30648.	7.1	25

#	Article	IF	Citations
127	Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. Journal of Neurology, 2015, 262, 2425-2432.	3.6	24
128	History of fatigue in multiple sclerosis is associated with grey matter atrophy. Scientific Reports, 2019, 9, 14781.	3.3	24
129	Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis. JAMA Network Open, 2021, 4, e2134627.	5.9	23
130	Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models. NeuroImage: Clinical, 2015, 8, 606-610.	2.7	21
131	In vivo anti-LAP mAb enhances IL-17/IFN-Î³ responses and abrogates anti-CD3-induced oral tolerance. International Immunology, 2015, 27, 73-82.	4.0	21
132	A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. Journal of the Neurological Sciences, 2017, 383, 221-229.	0.6	20
133	Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells. Multiple Sclerosis Journal, 2019, 25, 63-71.	3.0	20
134	Antiidiotypic antibody to reovirus binds to neurons and protects from viral infection. Annals of Neurology, 1986, 19, 555-558.	5.3	19
135	SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. Multiple Sclerosis Journal, 2018, 24, 1485-1498.	3.0	19
136	IL-6 Inhibits Upregulation of Membrane-Bound TGF-Î² 1 on CD4+ T Cells and Blocking IL-6 Enhances Oral Tolerance. Journal of Immunology, 2017, 198, 1202-1209.	0.8	18
137	PD-L1+ and XCR1+ dendritic cells are region-specific regulators of gut homeostasis. Nature Communications, 2021, 12, 4907.	12.8	18
138	Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	17
139	The microbiota restrains neurodegenerative microglia in a model of amyotrophic lateral sclerosis. Microbiome, 2022, 10, 47.	11.1	17
140	Oral tolerance: Elucidation of mechanisms and application to treatment of autoimmune diseases. , 1997, 43, 323-335.		16
141	Mucosal administration of CD3-specific monoclonal antibody inhibits diabetes in NOD mice and in a preclinical mouse model transgenic for the CD3 epsilon chain. Journal of Autoimmunity, 2017, 76, 115-122.	6.5	16
142	Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis. ENeurologicalSci, 2018, 12, 42-46.	1.3	16
143	Time between expanded disability status scale (EDSS) scores. Multiple Sclerosis and Related Disorders, 2019, 30, 98-103.	2.0	16
144	Î³Î´ T Cellâ€“Secreted XCL1 Mediates Anti-CD3â€“Induced Oral Tolerance. Journal of Immunology, 2019, 203, 2621-2629.	0.8	16

#	Article	IF	Citations
145	Survivin controls biogenesis of microRNA in smokers: A link to pathogenesis of rheumatoid arthritis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 663-673.	3.8	15
146	The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 17, 47-53.	2.0	15
147	Proximal and distal effects of genetic susceptibility to multiple sclerosis on the T cell epigenome. Nature Communications, 2021, 12, 7078.	12.8	15
148	How does the immune system tolerate food?. Science, 2016, 351, 810-811.	12.6	14
149	Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice. Clinical Immunology, 2017, 183, 240-246.	3.2	14
150	The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis. Journal of the Neurological Sciences, 2019, 403, 38-43.	0.6	14
151	Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 18, 196-201.	2.0	13
152	Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis. Crohn's & Colitis 360, 2019, 1, otz009.	1.1	13
153	Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study. Frontiers in Immunology, 2021, 12, 709861.	4.8	13
154	How does Epstein-Barr virus trigger MS?. Immunity, 2022, 55, 390-392.	14.3	13
155	The Effect of Fingolimod on Conversion of Acute Gadoliniumâ€Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis. Journal of Neuroimaging, 2016, 26, 184-187.	2.0	12
156	Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis. International Journal of Neuroscience, 2017, 127, 971-980.	1.6	12
157	Regional microglial activation in the substantia nigra is linked with fatigue in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	12
158	Protein Degradome of Spinal Cord Injury: Biomarkers and Potential Therapeutic Targets. Molecular Neurobiology, 2020, 57, 2702-2726.	4.0	12
159	Cellular Components and Mechanisms of Oral Tolerance Induction. Critical Reviews in Immunology, 2018, 38, 207-231.	0.5	12
160	Oral tolerance: an updated review. Immunology Letters, 2022, 245, 29-37.	2.5	12
161	Clonally restricted B cells in peripheral blood of multiple sclerosis patients: Kappa/lambda staining patterns. Annals of Neurology, 1982, 11, 408-412.	5.3	11
162	Role of Mast Cells in Peripheral Nervous System Demyelination. Annals of the New York Academy of Sciences, 1988, 540, 727-728.	3.8	11

#	Article	IF	Citations
163	Magnetic Resonance Imaging Surrogates of Multiple Sclerosis Pathology and Their Relationship to Central Nervous System Atrophy. Journal of Neuroimaging, 2004, 14, 46S.	2.0	11
164	Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study. Journal of Neuroimaging, 2020, 30, 212-218.	2.0	11
165	Early Predictors of Clinical and <scp>MRI</scp> Outcomes Using <scp>Least Absolute Shrinkage and Selection Operator (LASSO)</scp> in Multiple Sclerosis. Annals of Neurology, 2022, 92, 87-96.	5.3	11
166	Treatment of Autoimmune Diseases by Oral Tolerance to Autoantigens. Autoimmunity, 1993, 15, 6-7.	2.6	10
167	Effect of Natalizumab Treatment on Circulating Plasmacytoid Dendritic Cells: A Cross-Sectional Observational Study in Patients with Multiple Sclerosis. PLoS ONE, 2014, 9, e103716.	2.5	10
168	A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis. International Journal of Neuroscience, 2017, 127, 396-403.	1.6	10
169	Latent-period stool proteomic assay of multiple sclerosis model indicates protective capacity of host-expressed protease inhibitors. Scientific Reports, 2019, 9, 12460.	3.3	10
170	Serum antibodies to phosphatidylcholine in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e765.	6.0	10
171	Regulation of splenic monocyte homeostasis and function by gut microbial products. IScience, 2021, 24, 102356.	4.1	10
172	Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1791-1799.	3.0	9
173	Serum neurofilament levels and patientâ€reported outcomes in multiple sclerosis. Annals of Clinical and Translational Neurology, 2021, 8, 631-638.	3.7	9
174	Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis. NeuroImage, 2015, 119, 81-88.	4.2	8
175	Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate. Journal of the Neurological Sciences, 2018, 394, 127-131.	0.6	8
176	A One-Two Punch in the Gut May Trigger Multiple Sclerosis. Immunity, 2020, 53, 707-709.	14.3	8
177	Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 593-602.	3.0	8
178	MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. Journal of Neuroimaging, 2021, 31, 388-393.	2.0	8
179	Mucosal tolerance therapy in humans: Past and future. Clinical and Experimental Neuroimmunology, 2019, 10, 20-31.	1.0	7
180	Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731982840.	1.0	7

#	Article	IF	Citations
181	Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110155.	1.0	7
182	Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 40, 101944.	2.0	7
183	Review of Phase III Clinical Trials Outcomes in Patients with Secondary Progressive Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2021, 54, 103086.	2.0	6
184	Widespread Glial Activation in Primary Progressive Multiple Sclerosis Revealed by 18F-PBR06 PET. Clinical Nuclear Medicine, 2021, 46, 136-137.	1.3	6
185	Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis. Quality of Life Research, 2022, 31, 1799-1805.	3.1	6
186	The fine line between autoimmune and allergic encephalomyelitis. Nature Immunology, 2001, 2, 193-194.	14.5	5
187	A pharmacogenetic study implicates NINJ2 in the response to Interferon-Î² in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1074-1082.	3.0	5
188	The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110075.	1.0	5
189	The microbiome requires a genetically susceptible host to induce central nervous system autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27764-27766.	7.1	5
190	Loss of Functional Suppression Is Linked to Decreases in Circulating Suppressor-Inducer (CD4+2H4+) T Cells in Multiple Sclerosis. Annals of the New York Academy of Sciences, 1988, 540, 330-332.	3.8	4
191	Visualizing Lymph Node Structure and Cellular Localization using Ex-Vivo Confocal Microscopy. Journal of Visualized Experiments, 2019, , .	0.3	4
192	Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732199907.	1.0	4
193	Temporal trends of multiple sclerosis disease activity: Electronic health records indicators. Multiple Sclerosis and Related Disorders, 2022, 57, 103333.	2.0	4
194	Myeloid cell subsets that express latency-associated peptide promote cancer growth by modulating TÃcells. IScience, 2021, 24, 103347.	4.1	4
195	Cumulative Experience with High-Dose Intravenous Cyclophosphamide and ACTH Therapy in Chronic Progressive Multiple Sclerosis. Annals of the New York Academy of Sciences, 1988, 540, 535-536.	3.8	3
196	Validation of Two Kinetic Assays for the Quantification of Endotoxin in Human Serum. Frontiers in Neurology, 2021, 12, 691683.	2.4	3
197	Nasal administration of amyloidâ€Î² peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Annals of Neurology, 2000, 48, 567-579.	5.3	3
198	Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2022, 62, 103793.	2.0	3

#	Article	IF	Citations
199	Connecting up. Nature, 1988, 335, 475-475.	27.8	2
200	Immunohistochemical Analysis of Suppressor-Inducer and Helper-Inducer T Cells in Multiple Sclerosis Brain Tissue. Annals of the New York Academy of Sciences, 1988, 540, 306-308.	3.8	2
201	Reply to â€œDetecting oxysterols in the human circulationâ€. Nature Immunology, 2011, 12, 577-578.	14.5	2
202	Gene Activation During Experimental Allergic Encephalomyelitis.. Annals of the New York Academy of Sciences, 1988, 540, 264-265.	3.8	1
203	ISDN2014_0027: REMOVED: Identification of a unique molecular and functional microglia signature in health and disease. International Journal of Developmental Neuroscience, 2015, 47, 5-5.	1.6	1
204	ISDN2014_0028: REMOVED: Targeting miRâ€155 restores dysfunctional microglia and ameliorates disease in the SOD1 model of ALS. International Journal of Developmental Neuroscience, 2015, 47, 5-5.	1.6	1
205	Inducing tolerance one antigen at a time. Nature Biotechnology, 2016, 34, 515-517.	17.5	1
206	The emergence of neuroepidemiology, neurovirology and neuroimmunology: the legacies of John F. Kurtzke and Richard â€˜Dickâ€™ T. Johnson. Journal of Neurology, 2017, 264, 817-828.	3.6	1
207	Obesity is associated with the Optic Neuritis severity in Male patients with Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2021, 51, 102910.	2.0	1
208	Targeting Epstein-Barr virus to treat MS. Med, 2022, 3, 159-161.	4.4	1
209	TrbK controls astrocyte-driven oligodendrocyte copper poisoning. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2110998118.	7.1	0